ArticleInternational journal of clinical and experimental pathology2015
Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Accuracy Evaluation and Comparison of 14 Diagnostic Markers for Nasopharyngeal Carcinoma: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Utility of Serum EB Virus Zta Antibody in the Diagnostic of Nasopharyngeal Carcinoma: Evidences From 2,126 Cases and 15,644 Controls.Frontiers in oncology · 2019Pooled it
- A novel serum protein biomarker for the late-stage diagnosis of nasopharyngeal carcinoma.BMC cancer · 2025Article
- The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis.Cancer cell international · 2021Review
- Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.Pathology oncology research : POR · 2020Article
- Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma.Journal of Cancer · 2020Article
- Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.Cancer research and treatment · 2019Article
- Molecular Grading of Oral Squamous Cell Carcinomas Infected with EBVAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.Annals of hematology · 2017Article
- Integrative analysis of BSG expression in NPC through immunohistochemistry and public high-throughput gene expression data.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) is an important non-invasive index for nasopharyngeal carcinoma. Serum sialic acid (SA) level was known to be related with tumor progression. Rta protein antibody IgG (Rta-IgG), early antigen antibody (EA-IgA) and viral capsid antibody (VCA-IgA) levels in serum can also be used to effectively monitor the progression of cancer. This study investigated serum level of SA, Rta-IgG, EA-IgA and VCA-IgA in nasopharyngeal cancer patients and the diagnostic value of combined assay. A total of 64 nasopharyngeal cancer patients were recruited, in parallel with 60 benign rhinitis and 60 healthy individuals. Serum SA, EA-IgA, Rta-IgG and VCA-IgA levels were measured by enzyme-linked immunosorbent assay (ELISA). The diagnostic value of these indexes was further evaluated by ROC curve analysis. Logistic regression model was used to analyze the diagnostic implication of combined assay. The expression levels of SA, EA-IgA, Rta-IgG, and VCA-IgA were highest in nasopharyngeal cancer patients. Those indexes were also increased with advanced TNM stage of cancer. The overall diagnostic efficacy was ranked as: VCA-IgA, Rta-IgA, EA-IgA and SA. The combined diagnosis increased the sensitivity to 98.44% and the negative predictive value to 99.03%, without compromising specificity. SA, EA-IgA, Rta-IgG and VCA-IgA expression levels were elevated in nasopharyngeal patients. The combined diagnosis of those serum indexes may improve the diagnostic efficacy of nasopharyngeal carcinoma.
Indexed as
Identifiers
26884888PMC4730101W2411576907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.